Vertex Corrects Cystic Fibrosis Data; Shares Fall

By Rod Raynovich: Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost

Prohost Biotech submits: This article was originally published on February 26, 2011

By The Burrill Report: By Vinay Singh

By Prohost Biotech:On Monday May 7, 2012, Vertex (VRTX) announced an interim analysis of data from an ongoing Phase 2 study of VX-809 in combination with Kalydeco (ivacaftor).

By Dividend Kings:Vertex (VRTX) shot up 41% during intraday trading recently after a Cystic Fibrosis study concluded that 46% of patients had improved lung function after taking a combination of Kalydeco and the experimental VX-809 drug. The finding could boost the eligible patient pool by up to ten times.

Improved Lung Function Cited Vertex Pharmaceuticals said its VX-661 compound improved breathing for patients suffering from cystic fibrosis. The Phase II study combined the drug with another one of the ...

By Prohost Biotech:This article is not about Vertex (VRTX), but we could not refrain from expressing our anger about the high-tech slaughter of VRTX on Thursday June 28, 2012. What happens in such situations benefits only those who bet against excellent biotech stocks, who know, in fact, that if the prices continue to rally, they can still do whatever it takes to bring them d

By Ry Frank:Vertex Pharmaceuticals (VRTX) shares recently dropped 20% on the news that its VX-809/Kalydeco Cystic Fibrosis combination therapy data had been inflated. Instead of 46% of the patients in the Phase II studies showing an improvement in lung function of 5% or more, the actual figure was 35%.